BeOne Medicines stock analysis: Brukinsa drove 29.6% revenue growth and strong margins, but a 64.06 P/E keeps the model’s signal at Hold.
@2026 – All Right Reserved.
Tag:
Health Care
-
-
Health Care EquipmentUS Stocks
Intuitive Surgical Sits 33% Below Its Two-Year High – Why a 95/100 Quality Score Still Only Earns a Hold
Intuitive Surgical stock analysis: ISRG earns a 95/100 Quality score and 18.5% revenue growth, but a 46.12 P/E keeps the model at Hold.
-
BiotechnologyFeaturedUS Stocks
Incyte Grows Revenue 37.7% at a 15.46 P/E – Can It Outrun the 2028 Jakafi Patent Cliff?
Incyte stock analysis: INCY grows revenue 37.7% at a 15.46 P/E with a 98/100 Quality score. Why the model rates it a Buy despite the 2028 Jakafi cliff.
-
FeaturedPharmaceuticalsUS Stocks
United Therapeutics Rallies on Its Tyvaso IPF Filing – a 95/100 Quality Score at 19.4 Times Earnings
United Therapeutics stock analysis: UTHR rallies on its Tyvaso IPF filing with a 95/100 Quality score and a 19.40 P/E. Why the model rates it a Buy.
-
BiotechnologyUS Stocks
Faeth Therapeutics Trades Near Its Two-Year High While the Fundamentals Stay Pre-Revenue
Faeth Therapeutics stock analysis: a pre-revenue clinical biotech trading near its two-year high, with no debt, steep losses and a model rating of N/A.
-
BiotechnologyUS Stocks
Madrigal’s Revenue Is Up 71% as Rezdiffra Ramps – the Stock Is Already Near Its Highs
Madrigal Pharmaceuticals stock analysis: 71% revenue growth meets a rich 24x price-to-book near two-year highs. Model signal: Hold.
-
BiotechnologyUS Stocks
IDEAYA Biosciences: Trading Near a Two-Year High While the Model Flags a Sell
IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.
Newer Posts